This study is a single-arm, open-label, phase I/II trial designed to find a CMP-001 dose
that, in combination with pembrolizumab, has optimal clinical efficacy and acceptable
toxicity for patients with relapsed and refractory lymphomas.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Umar Farooq
Collaborators:
Checkmate Pharmaceuticals Merck Sharp & Dohme Corp. University of Iowa